Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

Add GTBP Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 2/23/2021 8:03:17 PM - Followers: 172 - Board type: Free - Posts Today: 0


The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.

What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 


Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   

GT Biopharma Portfolio

GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.

Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."


Company Website

GTBP Investor's Overview


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 02/22/2021 02:42:55 PM
GTBP News: Current Report Filing (8-k) 02/18/2021 06:05:42 AM
GTBP News: Statement of Ownership (sc 13g) 02/17/2021 04:08:16 PM
GTBP News: Prospectus Filed Pursuant to Rule 424(b)(4) (424b4) 02/12/2021 06:12:00 AM
GTBP News: Current Report Filing (8-k) 02/11/2021 08:22:30 AM
News News Alert: GT Biopharma Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer 03/08/2021 08:30:00 AM
#18555   Bidding $2.49 here Disquisition 02/23/21 08:03:17 PM
#18554   i have been there before ! most reverse ShortSale4U 02/23/21 01:38:50 PM
#18553   i have been there before ! most reverse ShortSale4U 02/23/21 01:38:43 PM
#18552   With phase I coming to an end by OilRush 02/16/21 10:37:02 AM
#18551   Today was a solid return. I expect many Sage7243 02/12/21 07:12:59 PM
#18550   If you have a small position that would Jacque_Strap 02/11/21 11:57:48 PM
#18549   I currently have a small position but am Sage7243 02/11/21 08:08:47 PM
#18548   I don’t think so. It’s obvious your a shorter and Jacque_Strap 02/11/21 06:56:53 PM
#18547   Good choice. They raised well over $20,000,000. Going forward there Jacque_Strap 02/11/21 06:55:12 PM
#18546   I have been waiting for the uplist and Sage7243 02/11/21 05:23:33 PM
#18545   This could be good news vs bad news Jacque_Strap 02/11/21 11:37:53 AM
#18544   you all just got taken. This will be ShortSale4U 02/11/21 09:54:18 AM
#18543   GT Biopharma Inc., GTBP, moved to the Nasdaq Renee 02/11/21 09:25:07 AM
#18542   https://www.businesswire.com/news/home/20210211005288/en/ Otis T 02/11/21 08:18:09 AM
#18541   GTBP one for 17 reverse split. "Company is Renee 02/10/21 04:45:14 PM
#18540   At only 79M outstanding shares, why wouldn't this OilRush 01/29/21 10:51:56 AM
#18539   Removing the small investor with the r/s. Bpps 01/23/21 08:49:26 AM
#18538   Gtbp here we go lagunatix 01/06/21 11:28:16 AM
#18537   Same. Not much liquidity on this one but Plummy Potter 01/03/21 03:42:34 PM
#18536   Took a bit of a dive but I'm ElleDe 12/30/20 07:07:21 PM
#18535   Strong accumulation @ this level. Poised for another breakout above 0.77. Jacque_Strap 12/28/20 01:07:17 PM
#18534   Why is this board so dead? OilRush 12/27/20 02:06:31 AM
#18533   Didn't they do this in 2017 with the Bpps 12/18/20 08:33:51 AM
#18532   Thanks ElleDe! TechStock 12/17/20 04:52:05 PM
#18531   Yes https://twitter.com/EllleDe/status/1339539075016093696?s=19 ElleDe 12/17/20 06:53:33 AM
#18530   Does anyone know what GTBP is proposing for TechStock 12/17/20 06:31:52 AM
#18529   Unknown gem. ElleDe 12/15/20 05:29:00 PM
#18528   Yeah im suprirised this board is quiet too... TX MA 12/15/20 12:21:14 PM
#18527   GT Biopharma Submits Application for Uplisting to the ElleDe 12/14/20 09:08:58 AM
#18526   Positive news out. GTB 3550 Trike reduces bone marrow Jacque_Strap 12/08/20 05:33:44 PM
#18525   Same CEO who launched IOVA doogdilinger 10/26/20 09:24:02 AM
#18524   Addin' GTBP to radar here doogdilinger 10/26/20 09:23:10 AM
#18523   Cytovance bio & Gt Bio could be a Jacque_Strap 10/22/20 12:11:43 AM
#18522   Offerings being taken out slowly. I feel a buyout Jacque_Strap 10/21/20 03:37:39 PM
#18521   Bias continues on the upside. Read the tape. Breakout coming soon.. Jacque_Strap 10/21/20 01:04:17 PM
#18520   Trading very well if you are long. Accumulating @ Jacque_Strap 10/16/20 01:53:21 PM
#18519   GTBP has a long climb ahead of it conix 10/14/20 09:05:07 AM
#18518   Only about 30k @ 21.89. Very thin on the Jacque_Strap 10/09/20 11:41:22 AM
#18517   IS ANYBODY ELSE WATCHING THE NEWS moneemkr 08/04/20 09:10:03 PM
#18516   rallied big on that last dip. narrow spread TX MA 05/20/20 08:42:09 PM
#18515   .065 spread between bid & offer. .135-.20. Jacque_Strap 04/14/20 09:38:53 AM
#18514   Damn! The offering is sooo thin. Jacque_Strap 04/06/20 09:36:02 AM
#18513   I got the remainder filled yesterday.... growacet 03/17/20 11:34:56 AM
#18512   I'm in, just a partial fill so far.... growacet 03/16/20 10:39:30 AM
#18511   Guess that was all hype PR. If Gumby525 03/12/20 10:12:42 AM
#18510   What makes you think there is dilution? I eageleye 03/11/20 12:38:04 PM
#18509   Dilution and conversions will kill ya every time, Involuntary-Recluse 03/11/20 12:14:05 PM
#18508   GTBP is no HLTY folks :-) Involuntary-Recluse 03/11/20 11:48:37 AM
#18507   Looks like a large buy order and double eageleye 03/11/20 11:38:03 AM
#18506   Decent volume, not over the top, but decent. eageleye 03/11/20 10:56:08 AM
Consent Preferences